2024 EVENT SITE
WMIF MAIN SITEFirst Look: 15 rapid fire presentations
Fireside Chat: Albert Bourla, PhD, Chairman & CEO, Pfizer
KOL Focused Sessions – Block I of IV
Lunch and KOL Focused Sessions – Block II of IV
Opening Remarks
CEO Panel
Fireside Chat: Reshma Kewalramani, MD, CEO & President, Vertex Pharmaceuticals
Provider CEO Panel
Fireside Chat: Christophe Weber, President & CEO, Takeda Pharmaceuticals
The Innovation Gap: A Review of the future of Viral Vector Manufacturing and the Delivery of Genetic Medicines
A Deep Dive on Genetic Modalities for Rare Disease: Genetic Medicines Are Here
Opening Reception
KOL Focused Sessions – Block III of IV
Fireside Chat: Kate Walsh, Secretary of Health & Human Services, Commonwealth of Massachusetts
Fireside Chat: David Hyman, MD, CMO, Eli Lilly and Company
The Disruptors: Metabolic Power…Need It…Want It
The Innovation Gap: The Broader Impact of Metabolic Drugs on Related Diseases
Lunch and KOL Focused Sessions – Block IV of IV
Pioneering Digital Transformation
Capital Formation: Putting Money to Work – State of Affairs in Capital Markets
Fireside Chat: Toby Cosgrove, MD, former CEO & President, Cleveland Clinic and Marc Harrison, MD, Co-founder & CEO, HATCo
Fireside Chat
The Disruptors: The Biologic Revolution in Radiotherapies
The Innovation Gap: The Reemergence of ADCs Precision, T-cell engagers, and Bispecifics: Oncology at Its Finest
Attendee Reception and Dinner
The Disruptors: The Role of the Complement System in Inflammation and Inflammatory Diseases
Fireside Chat: Stéphane Bancel, CEO, Moderna
The Innovation Gap: Understanding the Role of Cell Therapies in Autoimmune Disease
Unmet Needs Panel with Harvard KOLs
Fireside Chat: Scott Gottlieb, MD, PhD, Former Commissioner, United States Food and Drug Administration (2017-2019)